Cargando…
Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?
Purpose: Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an invaluable drug target for the pharmacological management of pituitary adenomas and neuroendocrine tumors. Furthermore, somatostatin (SST) receptors (SSTR1, 2A and B, 3, 4 and 5) belong to the G protei...
Autores principales: | Domvri, Kalliopi, Bougiouklis, Dimitrios, Zarogoulidis, Paul, Porpodis, Konstantinos, Xristoforidis, Manolis, Liaka, Alexandra, Eleutheriadou, Ellada, Lampaki, Sofia, Lazaridis, George, Organtzis, John, Kyriazis, George, Hohenforst-Schmidt, Wolfgang, Tsirgogianni, Katerina, Karavasilis, Vasilis, Baka, Sofia, Darwiche, Kaid, Freitag, Lutz, Trakada, Georgia, Zarogoulidis, Konstantinos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349876/ https://www.ncbi.nlm.nih.gov/pubmed/25767606 http://dx.doi.org/10.7150/jca.11308 |
Ejemplares similares
-
Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
por: Porpodis, Konstantinos, et al.
Publicado: (2015) -
Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer
por: Lampaki, Sofia, et al.
Publicado: (2015) -
New dilemmas in small-cell lung cancer TNM clinical staging
por: Zarogoulidis, Konstantinos, et al.
Publicado: (2013) -
Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013) -
Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)